Skip to content

The effect of ciprofol on gastrointestinal motility in patients undergoing laparoscopic radical resection for colorectal cancer: a prospective, single center, single blind, randomized controlled study

The effect of ciprofol on gastrointestinal motility in patients undergoing laparoscopic radical resection for colorectal cancer: a prospective, single center, single blind, randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093434
Enrollment
Unknown
Registered
2024-12-05
Start date
2025-04-10
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative gastrointestinal dysfunction

Interventions

Ciprofol group:General anesthesia induction and maintain with ciprofol
Propofol group:General anesthesia induction and maintain with propofol

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old; 2. BMI is 18~30kg/^2; 3. Planned laparoscopic radical colorectal cancer surgery; 4. NYHA cardiac function grade I-II; 5. ASA grading I-III; 6. Patients and their families understand this study, voluntarily participate in this trial, and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of allergy to the drugs used; 2. Current and long-term use of analgesics, psychotropic drugs, hormones, drugs affecting gastrointestinal motility (morpholine, mosapride, M1 receptor agonist/inhibitor, etc.) or non-steroidal anti-inflammatory drugs; 3. Respiratory insufficiency, presence of difficult airway or judged to be difficult to endotracheal intubation (modified Mahaloban score of grade III. or IV); 4. Patients with severe organic diseases, organ dysfunction or electrolyte disorders. 5. Patients with previous mental and neurological diseases: such as depression, Parkinson's disease, basal gangliopathy, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, cerebrovascular accident, etc.; 6. Patients who are considered by the investigator to be inappropriate to participate in the trial; 7. Participation in another study within 4 weeks prior to the current trial; 8. Patients with drug and alcohol abuse.

Design outcomes

Primary

MeasureTime frame
Time to first postoperative flatus;

Secondary

MeasureTime frame
Incidence of postoperative gastrointestinal intolerance;Hospitalization costs;First meal intake time after surgery;Incidence of postoperative gastrointestinal dysfunction;First defecate time after surgery;Postoperative hospital length of stay;Hemodynamic suppression:(1) incidence of hypotension;(2) incidence of sinus bradycardia;

Countries

China

Contacts

Public ContactYaomin Zhu

The First Affiliated Hospital of Xi'an Jiaotong University

zhuyaomin_mzk@163.com+86 18629382846

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026